Abstract
Pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, has shown promising antitumor activity and manageable toxicity in HER2-positive metastatic breast cancer. However, the efficacy and safety of pyrotinib-based treatment in the real-world setting in China is limited. The aim of this study was to evaluate actual clinical outcomes in HER2-positive metastatic breast cancer treated with pyrotinib.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
